全文获取类型
收费全文 | 71243篇 |
免费 | 7460篇 |
国内免费 | 5377篇 |
专业分类
耳鼻咽喉 | 683篇 |
儿科学 | 965篇 |
妇产科学 | 1164篇 |
基础医学 | 7957篇 |
口腔科学 | 1411篇 |
临床医学 | 8894篇 |
内科学 | 9944篇 |
皮肤病学 | 825篇 |
神经病学 | 3642篇 |
特种医学 | 2677篇 |
外国民族医学 | 30篇 |
外科学 | 7831篇 |
综合类 | 12955篇 |
现状与发展 | 21篇 |
一般理论 | 8篇 |
预防医学 | 5190篇 |
眼科学 | 1664篇 |
药学 | 7489篇 |
57篇 | |
中国医学 | 4736篇 |
肿瘤学 | 5937篇 |
出版年
2024年 | 178篇 |
2023年 | 1099篇 |
2022年 | 2063篇 |
2021年 | 3843篇 |
2020年 | 2934篇 |
2019年 | 2453篇 |
2018年 | 2606篇 |
2017年 | 2506篇 |
2016年 | 2259篇 |
2015年 | 3450篇 |
2014年 | 4248篇 |
2013年 | 4053篇 |
2012年 | 5654篇 |
2011年 | 5966篇 |
2010年 | 3877篇 |
2009年 | 3131篇 |
2008年 | 3792篇 |
2007年 | 3722篇 |
2006年 | 3539篇 |
2005年 | 3179篇 |
2004年 | 2466篇 |
2003年 | 2569篇 |
2002年 | 2275篇 |
2001年 | 1893篇 |
2000年 | 1628篇 |
1999年 | 1630篇 |
1998年 | 1009篇 |
1997年 | 968篇 |
1996年 | 752篇 |
1995年 | 686篇 |
1994年 | 611篇 |
1993年 | 313篇 |
1992年 | 458篇 |
1991年 | 393篇 |
1990年 | 361篇 |
1989年 | 295篇 |
1988年 | 292篇 |
1987年 | 237篇 |
1986年 | 198篇 |
1985年 | 128篇 |
1984年 | 100篇 |
1983年 | 53篇 |
1982年 | 29篇 |
1981年 | 25篇 |
1980年 | 32篇 |
1979年 | 22篇 |
1978年 | 15篇 |
1977年 | 10篇 |
1971年 | 8篇 |
1970年 | 11篇 |
排序方式: 共有10000条查询结果,搜索用时 64 毫秒
61.
肠易激综合征(Irritable bowel syndrome,IBS)是临床常见病、多发病,其治疗方法丰富,但部分患者疗效欠佳,发展成难治性IBS。目前国内外关于针灸治疗难治性IBS的临床随机对照试验尚不多见。本文立足试验方案设计的“PICOS”原则,从研究对象及诊断标准、干预措施、对照措施、结局指标四个方面入手,重点探讨针刺辅助治疗难治性肠易激综合征临床试验设计的关键要点。从选择特色优势病种、明确诊断标准、制定符合临床实际的干预方案、运用符合目标的安慰针刺、结合研究设计和目的选定结局指标几个角度,阐述试验相关环节设计的原因和思考。 相似文献
62.
Shiyu Jiang Yan Qin Hongxin Jiang Biao Liu Jianming Shi Fanlu Meng Peng Liu Jianliang Yang Sheng Yang Xiaohui He Shengyu Zhou Lin Gui Hao Liu Jing Lin Han Han-Zhang Yuankai Shi 《International journal of cancer. Journal international du cancer》2020,147(9):2611-2620
Diffuse large B-cell lymphoma (DLBCL) is a clinically aggressive and heterogenous disease. Although most patients can be cured by immunochemotherapy, 30% to 40% patient will ultimately develop relapsed or refractory disease. Here, we investigated the molecular landscapes of patients with diverse responses to R-CHOP. We performed capture-based targeted sequencing on baseline samples of 105 DLBCL patients using a panel consisting of 112 lymphoma-related genes. Subsequently, 81 treatment-naïve patients with measurable disease and followed for over 1 year were included for survival analysis. Collectively, the most commonly seen mutations included IGH fusion (69%), PIM1(33%), MYD88 (29%), BCL2 (29%), TP53 (29%), CD79B (25%) and KMT2D (24%). Patients with TP53 mutations were more likely to have primary refractory disease (87.0% vs 50.0%, P = .009). For those with TP53 disruptive mutations, 91.7% patients were in the primary refractory group. Interestingly, BCL-2 somatic hypermutation was only seen in patients without primary refractory disease (P = .014). In multivariate analysis, BCL-2 amplification (hazard ratio [HR] = 2.94, P = .022), B2M mutation (HR = 2.99, P = .017) and TP53 mutation (HR = 3.19, P < .001) were independently associated with shorter time to progression (TTP). Furthermore, TP53 mutations was correlated with worse overall survival (P = .049). Next, we investigated mutation landscape in patients with wild-type (WT) TP53 (n = 58) and found that patients harboring MYD88 L265P had significantly inferior TTP than those with WT or non-265P (P = .046). Our study reveals the mutation spectrum of treatment-naive Chinese DLBCL patients. It also confirms the clinical significance of TP53 mutations and indicates the prognostic value of MYD88 L265P in TP53 WT patients. 相似文献
63.
64.
65.
66.
Sequential Therapy Based on Evolvement of Patterns: A New Model for Treatment of Alzheimer’s Disease
In order to solve the problem of long-term (>9 months) efficacy in the treatment of Alzheimer''s disease (AD) by conventional therapy (CT), a staged and multiply-targeted sequential therapy based on the evolvement of patterns (STEP) was developed. Its main innovations include: (1) the time order of evolution of patterns defined by Chinese medicine (CM) in AD was found, that is, "the orderly pattern evolution starting from Shen (Kidney) deficiency, progressing to phlegm, stasis and fire, and worsening to severe toxin as well as functional collapse"; (2) the cascade hypothesis of Shen deficiency in AD and its sequential therapy based on Shen-reinforcing was proposed, that is, "reinforcing Shen in the early stage and throughout the whole process, resolving phlegm, activating blood and purging fire in the middle stage, detoxifying and replenishing vitality to stop the collapse in the advanced stage", and through meta-analysis, clinical drug use was optimized, thus the leap from "inferential selection" to "evidence-based selection" was realized; (3) the STEP regimen combined with CT maintained cognitive and behavioral stability in AD patients for at least 12 months, with cognitive enhancement and behavioral synergy after 9 months, and cognitive benefit was superior to CT at 9, 12, 15, 18, 21, and 24 months, respectively. The 2-year cognitive improvement rate was increased by 25.64% (P=0.020) and the cognitive deterioration rate was decreased by 48.71% (P=0.000). Among them, the cognitive and functional benefits of Shen-reinforcing therapy for very early AD (350 cases) for 1 year were better than the placebo (P<0.001), and the dementia conversion rate was reduced by 8.85% (P=0.002). The behavioral symptomatic relief of patients with vascular dementia received fire-purging therapy (540 cases) was superior to those received CT (P=0.016). These data suggested that the STEP regimen has synergistic effects on CTs at least in terms of cognitive benefit, and the earlier the use, the greater the benefit will have. Therefore, the STEP regimen should be considered as one of the clinical options, particularly for the dearth of effective pharmaceutical or immunological interventions that are currently available for AD. 相似文献
67.
背景与目的:甲状腺乳头状癌(papillary thyroid carcinoma,PTC)和桥本甲状腺炎(Hashimoto’s thyroiditis,HT)的发病率均呈上升趋势,两者之间的关系已成为目前研究的热点。探讨PTC和HT之间的关系。方法:回顾性分析2014—2015年期间在中国科学院大学附属肿瘤医院头颈肿瘤外科行甲状腺癌手术治疗的首诊患者306例,术后病理学检查均明确诊断为PTC,其中术后病理学确诊伴发HT者42例,比较伴发HT与未伴发HT患者的临床病理学特征。结果:PTC患者女性发病年龄高于男性(46.2岁 vs 41.9岁)。相较于与未伴发HT的PTC患者,伴发HT的患者中女性比例更高(93% vs77%),中央区淋巴结数目较多[(5.0±3.4)枚 vs (2.5±2.7)枚],术前促甲状腺激素(thyroid-stimulating hormone,TSH)水平较高[(3.28±1.91)μU/mL vs (2.12±1.29)μU/mL],术前抗甲状腺过氧化物酶抗体(thyroid peroxidaseantibody,TPOAb)阳性率较高(55% vs 14%),术前甲状腺球蛋白抗体(thyroglobulin antibodies,TgAb)阳性率较高(69% vs 13%)。发生中央区淋巴结转移的患者中,中央区淋巴结转移数目与中央区淋巴结总数显著相关(Pearson相关系数=0.582)。多因素logistic回归分析发现,男性、低龄、被膜侵犯是PTC患者中央区淋巴结转移的独立危险因素。结论:伴发HT对PTC患者的预后无显著影响。伴发HT的PTC患者TSH水平显著偏高,提示HT可能是PTC发病风险因素之一。中央区淋巴结转移数目与中央区淋巴结总数相关,推测PTC淋巴结转移可能与淋巴结炎症反应相关。 相似文献
68.
MOB1A regulates glucose deprivation-induced autophagy via IL6-STAT3 pathway in gallbladder carcinoma
Bo Yang Yang Li Rui Zhang Liguo Liu Huijie Miao Yongsheng Li Ziyu Shao Tai Ren Yijian Zhang Qiyu Zhang Yingbin Liu Hongqi Shi 《American journal of cancer research》2020,10(11):3896
MOB kinase activator 1A (MOB1A) plays an important role in many diseases and cancers. Here, we observed that MOB1A was substantially overexpressed in gallbladder carcinoma (GBC) tissues compared with nontumor tissues. The high expression of MOB1A was closely associated with poor survival in patients with GBC at advanced TNM stages. Furthermore, our study indicated that MOB1A promoted autophagy by activating the IL6/STAT3 signaling pathway and regulating the chemosensitivity to gemcitabine under glucose deprivation conditions both in vitro and in vivo. In conclusion, these findings suggested that MOB1A is critical for the development of GBC via the MOB1A-IL6/STAT3-autophagy axis. 相似文献
69.
目的评估消化道恶性肿瘤患者的能量消耗,探讨最佳计算公式及能量消耗的影响因素。方法采用连续入组法,纳入2016年3月至2016年12月在陆军军医大学第一附属医院肿瘤科住院治疗患者,运用代谢车测定其静息代谢能量(REE),使用Harris-Benedict公式和30kcal/(kg·d) 公式预测患者的一日总能量消耗(TEE)。收集研究对象的相关指标如年龄、身高、体重、病程、原位癌部位、是否荷瘤等。结果共纳入26例患者,其中包括食管癌11例,胃癌8例,结直肠癌7例,73%的患者处于高代谢状态,约69%的患者处于肿瘤Ⅳ期;其中不同病程和原位癌位置与静息能量消耗有差异,差异具有统计学意义;用30kcal/(kg·d)×体重估算TEE可能并不适用于消瘦的消化道肿瘤患者。结论消化道恶性肿瘤患者大多存在营养不良且处于高代谢状态,在给消化道恶性肿瘤患者提供能量时应适当考虑病程长短、肿瘤分期以及肿瘤部位等因素。尽量使用代谢车估算恶性肿瘤患者的TEE,若没有代谢车条件时,对于能下床活动的消化道恶性肿瘤患者,体质指数(BMI)≥18.5kg/m2者推荐使用30kcal/(kg·d)×实际体重的方法估算TEE,BMI<18.5kg/m2者推荐使用30kcal/(kg·d)×标准体重的方法估算TEE。 相似文献
70.
公立医院运营管理的思考与建议 《医学教育管理》2020,6(4):391-394
随着医改的不断深入和建立现代医院管理制度的迫切要求,公立医院面临全新的挑战,向管理要效益是实现医院内涵式发展的重要途径。从当前公立医院运营管理的现状入手,通过深入分析存在的问题,为进一步推进公立医院运营管理建设提出思路和建议,对实现公立医院管理转型,提升医院管理水平,实现科学化、精益化管理提供借鉴。 相似文献